It said that 95% of people with cystic fibrosis in England will now be eligible for modulator therapy. The new drug, also ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

BiomX has dosed the first subject in the randomised Phase IIb trial of the company’s fixed multi-phage therapy, BX004, to ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

The new pill is seen as a ‘major leap forward’ for hundreds of patients living with the rarest forms of cystic fibrosis ...

A once-a-day pill health experts are calling 'life-changing' will be offered to hundreds of people living with cystic ...

Hundreds of children and adults with rare forms of cystic fibrosis in England will be able to access “life-changing” new ‘triple-combination’ therapy for the very first time, the NHS has announced.

Alfie Coe, 13, from Terrington St Clement, will be running 3km daily during his school summer holidays to raise money for the ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

Alyftrek (vanzacaftor–tezacaftor–deutivacaftor), made by Vertex, represents the latest advance in CFTR modulator treatments that are transforming cystic fibrosis care by targeting the underlying cause ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...